Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 2Thyroid Diseases 1Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Paget Disease, Extramammary 1Lung Neoplasms 1Glioma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenolymphoma 1

Interventions

Temozolomide 42Magnetic Resonance Spectroscopy 41Radiotherapy 22Specimen Handling 18Biopsy 13X-Rays 10Radiation 10trametinib 8Bevacizumab 8Nivolumab 7Blood Specimen Collection 7olaparib 6fluorodopa F 18 6dabrafenib 6Radiotherapy, Intensity-Modulated 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Lomustine 6pembrolizumab 5abemaciclib 5Standard of Care 5vorasidenib 4ulixertinib 4larotrectinib 4ivosidenib 4erdafitinib 4Surgical Procedures, Operative 4Dianhydrogalactitol 4Cyclophosphamide 4Aminolevulinic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Fluorescein × 1 year × Clear all
NCT02691923 2025-08-03

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

Dartmouth-Hitchcock Medical Center

Phase 2 Recruiting
30 enrolled
CNS

Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡